Recent Finacing
Recent Raise
Convert Pharmaceuticals develops tumor‑microenvironment‑activated prodrugs focused on hypoxia‑activated cytotoxins; its lead candidate CP‑506, derived from University of Auckland research, is progressing toward initial clinical studies from Liège, Belgium.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
